The CEO's total reported compensation of approximately $35.9 million — driven by a single large award in February 2025 that was designed to cover multiple future years at once — is exceptionally high relative to what a typical CEO at a $2 billion biotech company would be paid, and almost certainly exceeds our +20% individual CEO benchmark threshold, triggering a no vote on pay level grounds alone. While the company structured much of this pay as performance-based equity tied to demanding stock price hurdles (requiring the share price to more than double to earn the first tranche), the incentive pay alignment test also fails: OCUL's stock gained only 12.9% over the past year while the XBI — SPDR S&P Biotech ETF gained 58.9% and the company's own peer group median gained 63.6%, meaning shareholders who held OCUL severely underperformed the biotech market in the same period that above-benchmark incentive awards were granted. Although the board engaged meaningfully with investors after the 2025 say-on-pay vote and the performance hurdles on the CEO's equity are genuinely rigorous, the combination of an outsized single-year compensation figure and significant near-term shareholder underperformance relative to XBI and peers does not pass the pay-for-performance alignment standard required by our policy.

Non-audit fees of $2,125 represent only about 0.1% of audit fees of $1,482,000, which is far below the 50% threshold that would raise independence concerns; PwC is a Big 4 firm appropriate for a $2B market-cap company; auditor tenure is not disclosed so the tenure trigger cannot fire; and no material financial restatements were identified.